RU2010107207A - Новые синтетические агонисты tlr9 - Google Patents

Новые синтетические агонисты tlr9 Download PDF

Info

Publication number
RU2010107207A
RU2010107207A RU2010107207/10A RU2010107207A RU2010107207A RU 2010107207 A RU2010107207 A RU 2010107207A RU 2010107207/10 A RU2010107207/10 A RU 2010107207/10A RU 2010107207 A RU2010107207 A RU 2010107207A RU 2010107207 A RU2010107207 A RU 2010107207A
Authority
RU
Russia
Prior art keywords
disease
disorder
patient
immune response
comprises administering
Prior art date
Application number
RU2010107207/10A
Other languages
English (en)
Other versions
RU2468819C2 (ru
Inventor
Экамбар Р. КАНДИМАЛЛА (US)
Экамбар Р. КАНДИМАЛЛА
ПУТТА Малликарджуна РЕДДИ (US)
ПУТТА Малликарджуна РЕДДИ
Дацин ВАН (US)
Дацин ВАН
Дун ЮЙ (US)
Дун ЮЙ
Бхагат ЛАКШМИ (US)
Бхагат ЛАКШМИ
Судхир АГРАВАЛ (US)
Судхир АГРАВАЛ
Original Assignee
Идера Фармасьютикалз, Инк. (Us)
Идера Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Идера Фармасьютикалз, Инк. (Us), Идера Фармасьютикалз, Инк. filed Critical Идера Фармасьютикалз, Инк. (Us)
Publication of RU2010107207A publication Critical patent/RU2010107207A/ru
Application granted granted Critical
Publication of RU2468819C2 publication Critical patent/RU2468819C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)

Abstract

1. Иммуномодулирующее соединение, выбранное из соединений № 1-№169. ! 2. Композиция, включающая иммуномодулирующее соединение по п.1 и физиологически приемлемый носитель. ! 3. Способ получения иммунного ответа у пациента, способ включает введение пациенту соединения по п.1 в фармацевтически эффективном количестве. ! 4. Способ терапевтического лечения пациента, имеющего заболевание или расстройство, где модуляция иммунного ответа будет полезной, такой способ включает введение пациенту соединения по п.1 в фармацевтически приемлемом количестве. ! 5. Способ по п.4, где заболеванием или расстройством является рак, аутоиммунное расстройство, воспалительное расстройство, инфекционное заболевание, кожное заболевание, аллергия, астма или заболевание, вызванное патогеном или аллергеном. ! 6. Способ по п.4, дополнительно включающий введение одного или более химиотерапевтических соединений, нацеленных терапевтических средств, вакцин, антигенов, антител, цитотоксических средств, аллергенов, антибиотиков, антисмысловых олигонуклеотидов, агонистов TLR, ингибиторов киназ, пептидов, белков, ДНК вакцин, адъювантов, ко-стимулирующих молекул или их комбинаций. ! 7. Способ профилактического лечения пациента, имеющего заболевание или расстройство, где будет полезной модуляция иммунного ответа, такой способ включает введение пациенту соединения по п.1 в фармацевтически эффективном количестве. ! 8. Способ по п.7, где заболеванием или расстройством является рак, аутоиммунное расстройство, воспалительное расстройство, инфекционное заболевание, кожное заболевание, аллергия, астма или заболевание, вызванное патогеном или аллергеном. ! 9. �

Claims (9)

1. Иммуномодулирующее соединение, выбранное из соединений № 1-№169.
2. Композиция, включающая иммуномодулирующее соединение по п.1 и физиологически приемлемый носитель.
3. Способ получения иммунного ответа у пациента, способ включает введение пациенту соединения по п.1 в фармацевтически эффективном количестве.
4. Способ терапевтического лечения пациента, имеющего заболевание или расстройство, где модуляция иммунного ответа будет полезной, такой способ включает введение пациенту соединения по п.1 в фармацевтически приемлемом количестве.
5. Способ по п.4, где заболеванием или расстройством является рак, аутоиммунное расстройство, воспалительное расстройство, инфекционное заболевание, кожное заболевание, аллергия, астма или заболевание, вызванное патогеном или аллергеном.
6. Способ по п.4, дополнительно включающий введение одного или более химиотерапевтических соединений, нацеленных терапевтических средств, вакцин, антигенов, антител, цитотоксических средств, аллергенов, антибиотиков, антисмысловых олигонуклеотидов, агонистов TLR, ингибиторов киназ, пептидов, белков, ДНК вакцин, адъювантов, ко-стимулирующих молекул или их комбинаций.
7. Способ профилактического лечения пациента, имеющего заболевание или расстройство, где будет полезной модуляция иммунного ответа, такой способ включает введение пациенту соединения по п.1 в фармацевтически эффективном количестве.
8. Способ по п.7, где заболеванием или расстройством является рак, аутоиммунное расстройство, воспалительное расстройство, инфекционное заболевание, кожное заболевание, аллергия, астма или заболевание, вызванное патогеном или аллергеном.
9. Способ по п.7, дополнительно включающий введение одного или более химиотерапевтических соединений, нацеленных терапевтических средств, вакцин, антигенов, антител, цитотоксических средств, аллергенов, антибиотиков, антисмысловых олигонуклеотидов, агонистов TLR, ингибиторов киназ, пептидов, белков, ДНК вакцин, адъювантов, ко-стимулирующих молекул или их комбинаций.
RU2010107207/10A 2007-08-01 2008-07-31 Новые синтетические агонисты tlr9 RU2468819C2 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US95325107P 2007-08-01 2007-08-01
US60/953,251 2007-08-01
US98360107P 2007-10-30 2007-10-30
US60/983,601 2007-10-30
US98715107P 2007-11-12 2007-11-12
US60/987,151 2007-11-12
US1529207P 2007-12-20 2007-12-20
US61/015,292 2007-12-20
PCT/US2008/071738 WO2009018431A2 (en) 2007-08-01 2008-07-31 Novel synthetic agonists of tlr9

Publications (2)

Publication Number Publication Date
RU2010107207A true RU2010107207A (ru) 2011-09-10
RU2468819C2 RU2468819C2 (ru) 2012-12-10

Family

ID=40305273

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010107207/10A RU2468819C2 (ru) 2007-08-01 2008-07-31 Новые синтетические агонисты tlr9

Country Status (13)

Country Link
US (2) US7960362B2 (ru)
EP (3) EP2173912A4 (ru)
JP (2) JP5563455B2 (ru)
KR (1) KR20100053598A (ru)
CN (3) CN102864151B (ru)
AU (1) AU2008282172B2 (ru)
BR (1) BRPI0813981A2 (ru)
CA (1) CA2693266C (ru)
ES (2) ES2585239T3 (ru)
HK (1) HK1216430A1 (ru)
IN (1) IN2010KN00195A (ru)
RU (1) RU2468819C2 (ru)
WO (1) WO2009018431A2 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
US8008267B2 (en) * 2003-06-11 2011-08-30 Idera Pharmaceuticals, Inc. Stabilized immunomodulatory oligonucleotides
WO2005009355A2 (en) * 2003-07-15 2005-02-03 Hybridon, Inc. Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
ES2585239T3 (es) * 2007-08-01 2016-10-04 Idera Pharmaceuticals, Inc. Nuevos agonistas sintéticos de TLR9
RU2011135993A (ru) * 2009-01-30 2013-03-10 Идера Фармасьютикалз, Инк. Новые синтетические агонисты tlr9
JP5759445B2 (ja) 2009-03-25 2015-08-05 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 病原体に対する哺乳類先天性免疫抵抗性の刺激のための組成物
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
JP6385957B2 (ja) * 2013-01-08 2018-09-05 イデラ ファーマシューティカルズ インコーポレイテッドIdera Pharmaceuticals, Inc. トール様受容体に基づく免疫応答を調節するための免疫調節オリゴヌクレオチド(iro)化合物
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
PL3164113T3 (pl) 2014-06-04 2019-09-30 Exicure, Inc. Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych
CA2961019A1 (en) * 2014-09-12 2016-03-17 Vantage Specialty Chemicals, Inc. Derivatives of 1,3-propanediol
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2016057898A1 (en) * 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2017052403A1 (ru) * 2015-09-25 2017-03-30 Анатолий Викторович ЗАЗУЛЯ Изготовление таблетки с механизмом повышения терапевтической эффективности лекарственного средства нанодозой микрорнк
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
MX2019002925A (es) 2016-09-15 2019-09-05 Idera Pharmaceuticals Inc Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3554344A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
TWI810193B (zh) 2017-07-05 2023-08-01 大陸商尚華醫藥科技(江西)有限公司 一種Kiss1肽類化合物、其應用及含其的組合物
EP3690030A4 (en) 2017-09-28 2021-06-23 Industry-Academic Cooperation Foundation, Yonsei University METHOD FOR MANUFACTURING MYELOID-DERIVED SUPPRESSOR CELLS, SUPPRESSOR CELLS MANUFACTURED FROM MYEOLID AND USES THEREOF
EP3993834A1 (en) 2019-07-05 2022-05-11 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
EP4175640A1 (en) 2020-07-02 2023-05-10 VIIV Healthcare Company Method of achieving hiv viral remission using long-acting antiretroviral agents
EP4192506A1 (en) 2020-08-07 2023-06-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6503734B1 (en) * 2000-07-26 2003-01-07 Cognis Corporation Cytochrome b5 gene and protein of Candida tropicalis and methods relating thereto
US6673613B2 (en) * 2000-07-26 2004-01-06 Cognis Corporation Use of CYP52A2A promoter to increase gene expression in yeast
RU2194502C2 (ru) * 2000-12-27 2002-12-20 Наровлянский Александр Наумович Иммуномодулятор - метаболик - детоксикант - адаптоген - радиопротектор
WO2002052002A2 (en) * 2000-12-27 2002-07-04 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
DK2423335T3 (da) * 2001-06-21 2014-08-18 Dynavax Tech Corp Kimæriske immunmodulatoriske forbindelser og fremgangsmåder til anvendelse deraf
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
SG2011035342A (en) * 2002-12-23 2016-12-29 Dynavax Tech Corp Immunostimulatory sequence oligonucleotides and methods of using the same
WO2004096156A2 (en) * 2003-04-29 2004-11-11 Centocor, Inc. Toll-like receptor 9 effector agents and uses thereof
US8008267B2 (en) * 2003-06-11 2011-08-30 Idera Pharmaceuticals, Inc. Stabilized immunomodulatory oligonucleotides
US20050244410A1 (en) * 2004-04-29 2005-11-03 Ashlyn Bassiri Toll-like receptor 9 effector agents and uses thereof
EP2901856B1 (en) * 2004-06-15 2017-08-09 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
US8357665B2 (en) * 2005-10-12 2013-01-22 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
JP5184366B2 (ja) * 2005-11-07 2013-04-17 イデラ ファーマシューティカルズ インコーポレイテッド 修飾された免疫刺激性ジヌクレオチドを含む、オリゴヌクレオチドに基づく化合物の免疫刺激特性
CA2632940A1 (en) * 2005-12-20 2007-07-05 Idera Pharmaceuticals, Inc. Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo tm) contiaining different lengths of palindromic segments
CN101610671A (zh) * 2006-12-12 2009-12-23 艾德拉药物股份有限公司 合成的tlr9激动剂
CA2699190A1 (en) * 2007-04-19 2009-10-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
ES2585239T3 (es) * 2007-08-01 2016-10-04 Idera Pharmaceuticals, Inc. Nuevos agonistas sintéticos de TLR9

Also Published As

Publication number Publication date
ES2539353T3 (es) 2015-06-30
HK1216430A1 (zh) 2016-11-11
WO2009018431A3 (en) 2009-12-30
EP2821488A2 (en) 2015-01-07
CN102864151A (zh) 2013-01-09
JP5816720B2 (ja) 2015-11-18
WO2009018431A2 (en) 2009-02-05
JP2010535242A (ja) 2010-11-18
JP2014205691A (ja) 2014-10-30
CN105177014A (zh) 2015-12-23
EP2173912A4 (en) 2013-03-20
EP2650369B1 (en) 2015-04-29
RU2468819C2 (ru) 2012-12-10
EP2821488B1 (en) 2016-07-27
EP2173912A2 (en) 2010-04-14
JP5563455B2 (ja) 2014-07-30
US20090053206A1 (en) 2009-02-26
EP2650369A1 (en) 2013-10-16
US20110311518A1 (en) 2011-12-22
ES2585239T3 (es) 2016-10-04
US7960362B2 (en) 2011-06-14
CN105177014B (zh) 2018-04-06
EP2821488A3 (en) 2015-04-29
CN101878311A (zh) 2010-11-03
BRPI0813981A2 (pt) 2017-05-09
CA2693266C (en) 2015-06-30
CA2693266A1 (en) 2009-02-05
KR20100053598A (ko) 2010-05-20
US8361986B2 (en) 2013-01-29
AU2008282172A1 (en) 2009-02-05
IN2010KN00195A (ru) 2015-08-28
AU2008282172B2 (en) 2014-05-22
CN102864151B (zh) 2015-07-08

Similar Documents

Publication Publication Date Title
RU2010107207A (ru) Новые синтетические агонисты tlr9
Cui et al. Synthetic double-stranded RNA poly (I: C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model
Vasilakos et al. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants
JP2010535242A5 (ru)
JP6406793B2 (ja) トール様受容体に基づく免疫反応を調整する免疫調節ヌクレオチド(iro)化合物
Meyer et al. Clinical investigations of Toll-like receptor agonists
AU2008265911B2 (en) Use of TLR agonists and/or type 1 interferons to alleviate toxicity of TNF-R agonist therapeutic regimens
EA200601761A1 (ru) Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения
Tomai et al. TLR7/8 agonists as vaccine adjuvants
Öhlschläger et al. The combination of TLR‐9 adjuvantation and electroporation‐mediated delivery enhances in vivo antitumor responses after vaccination with HPV‐16 E7 encoding DNA
NO20023829D0 (no) Proteosom influensavaksine
Kovacs-Nolan et al. The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody-and cell-mediated immune responses in mice
JP2008000001A (ja) 免疫刺激オリゴヌクレオチドおよびその医薬用途
NO20015073D0 (no) Vaksiner
CA2752694A1 (en) Synthetic rna-based agonists of tlr7
WO2002034205A3 (en) Using heat shock proteins to increase immune response
MXPA05009580A (es) Vacuna contra el virus de la influenza.
Lingnau et al. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines
CA2922320A1 (en) Enhanced photochemical internalisation using a tlr ligand
ES2581277T3 (es) Composición mejorada para inhibir la proliferación de células tumorales
Cheng et al. A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge
EA200801411A1 (ru) Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях
Maletzki et al. Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy
Dezfuli et al. Induction of IFN-γ cytokine response against hepatitis B surface antigen using melittin
RU2010101274A (ru) Применение мономиколилглицерина (mmg) в качестве адъюванта